title: [Effect of compound ezhu powder on serum levels of CA125 and CA19-9, and the expression of cyclin D protein in endometriosis patients].
abstract: OBJECTIVE
  To study the effect of Compound Ezhu Powder (CEP) on serum levels of CA125 and CA19-9, and the expression of cyclin D protein in endometriosis patients, thus providing theoretical evidence for clinical application of CEP.
  
  
  METHODS
  Totally 69 all endometriosis patients underwent surgical treatment at Department of Gynecology and Obstetrics, Tianjin Nankai Hospital from January 2011 to January 2013 were randomly assigned to group A (35 cases) and group B (34 cases). Meanwhile, 30 patients with uterine fibroids who prepared for surgical treatment during the same period were recruited as the control group. Patients in group A took EZP 3 months before surgery. No treatment was given to patients in group B and the control group. The serum CA125 level and the expression of cyclin D in the ectopic endometrium and the eutopic endometrium were detected in the 3 groups before surgery.
  
  
  RESULTS
  The expression of cyclin D was higher in group A and group B than in the control group (P < 0.05). The serum levels of CA125 and CA19-9 were significantly lower in group A than in group B (P < 0.05). The expression of cyclin D in the ectopic endometrium was lower in group A than in group B, but with no statistical difference (P > 0.05). The expression of cyclin D in the eutopic endometrium was significantly lower in group A than in group B with statistical difference (P < 0.05). Meanwhile, the serum CA125 level was positively correlated with the serum CA19-9 level (r = 0.45, P < 0.05).
  
  
  CONCLUSIONS
  The expression of cyclin D obviously increased in endometriosis patients, which was associated with the occurrence of endometriosis. CEP could lower serum levels of CA125 and CA19-9, and down-regulate the expression level of cyclin D, indicating its roles in inhibiting the cell cycle.
authors.forename: Ming
authors.initials: M
authors.lastname: Wei
authors.forename: Bao-Li
authors.initials: BL
authors.lastname: Cao
authors.forename: Yun
authors.initials: Y
authors.lastname: Liu
mesh_terms: D000328:Adult; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000097:blood*; D018394:CA-125 Antigen / Q000097:blood*; D018395:CA-19-9 Antigen / Q000097:blood*; D019938:Cyclin D1 / Q000378:metabolism*; D004365:Drugs, Chinese Herbal / Q000494:pharmacology*; D004715:Endometriosis / Q000097:blood* / Q000188:drug therapy; D005260:Female; D006801:Humans
chemical_list: D015295:Antigens, Tumor-Associated, Carbohydrate; D018394:CA-125 Antigen; D018395:CA-19-9 Antigen; C530104:CCND1 protein, human; D004365:Drugs, Chinese Herbal; D019938:Cyclin D1